EXOZYMES INC. — Form 8-K
Filed July 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On June 30, 2026, eXoZymes Inc. closed a securities placement with Public Ventures LLC (MDB Capital) as exclusive placement agent. The company sold 35,555 units at $18.00/unit (gross proceeds $639,990) consisting of 71,110 common shares ($8.99/share) and 35,555 warrants ($0.02/warrant). MDB received 7% commission ($44,799) plus up to $15,000 in expenses, plus warrants to purchase 10,666 shares at $11.24. Warrants exercisable June 5, 2027–June 5, 2031. Company bound by 12-month lockup (June 8, 2026–June 7, 2027) on capital raises. Net proceeds (~$560K) designated for N-trans-caffeoyltyramine (NCT) business development, R&D, and general corporate purposes.
Why this rating
Routine capital raise ~1.5% of company market cap; immaterial size relative to $38.4M valuation; standard terms.
Extracted items
- 1.01 material agreement
- 9.01 exhibits
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.